Kristin A Altwegg, Uday P Pratap, Zexuan Liu, Junhao Liu, John R Sanchez, Xue Yang, Behnam Ebrahimi, Durga Meenakshi Panneerdoss, Xiaonan Li, Gangadhara R Sareddy, Suryavathi Viswanadhapalli, Manjeet K Rao, Ratna K Vadlamudi
PURPOSE: Triple-negative breast cancer (TNBC) is the most aggressive subtype of breast cancer. Oncogenic PELP1 is frequently overexpressed in TNBC, and it has been demonstrated that PELP1 signaling is essential for TNBC progression. The therapeutic utility of targeting PELP1 in TNBC, however, remains unknown. In this study, we investigated the effectiveness of SMIP34, a recently developed PELP1 inhibitor for the treatment of TNBC. METHODS: To ascertain the impact of SMIP34 treatment, we used seven different TNBC models for testing cell viability, colony formation, invasion, apoptosis, and cell cycle analysis...
May 18, 2023: Breast Cancer Research and Treatment